Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | The gut microbiome & triple negative breast cancer

Grazia Vernaci • 14 May 2020
ESMO Breast 2020
Breast Cancer Carboplatin Checkpoint Inhibitors Cyclophosphamide

Grazia Vernaci, MD, University of Padova, Padova, Italy, discusses a trial evaluating the gut microbiome diversity and composition of a population of triple negative breast cancer (TNBC) patients treated with neo-adjuvant chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Grazia Vernaci

1:04
COVID-19 in Italy: managing breast cancer patients
Grazia Vernaci • 18 May 2020
0:41
The importance of BMI as a prognostic factor in breast cancer
Grazia Vernaci • 14 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals